Business Wire

The IBSA Class40 – the Craft That Will Take Alberto Bona to the Route Du Rhum – Was Launched in Trinité-Sur-Mer


Latest-generation Class40, “scow” bow, five months of production: the IBSA craft with which Alberto Bona will participate in the Route du Rhum in November was launched yesterday in La Trinité-Sur-Mer (Brittany, France). It’s the first project of the three-year program Sailing into the Future. Together that the ocean sailor started in early 2022, together with the Swiss pharmaceutical company.

This press release features multimedia. View the full release here:

To view this piece of content from, please give your consent at the top of this page.

Class40 IBSA: technical launch (Photo: © IBSA | Carlo Borlenghi)

Designed by Sam Manuard, one of the great French naval architects when it comes to ocean classes, the IBSA Class40 was built by the JPS Production shipyard. It’s a Mach 5 model, the latest evolution of Manuard’s Class40, and will be present at the start of the Route du Rhum as one of the most innovative and modern boats. Much attention will surely be drawn to the rounded bow, created with the aim of increasing performance when sailing downwind, but also the hull promises high performance, thanks to the shape of the water lines and appendages, designed to make it a fast all-rounder when reaching too. Distinctive is also the design of the cockpit, large and well protected: a choice that will allow the sailor to face navigation in the most comfortable and safe positions possible. “This boat perfectly reflects our approach to the program”, summarised Alberto Bona. “It’s the result of the search for detail, of the improvement in every single aspect: we were looking for a fast hull, clearly at the limits of the box rule, reliable in all weather conditions and sufficiently innovative to make a difference”.

The project Sailing into the Future. Togetherstarted from scratch last January with a partnership – that between IBSA and Alberto Bona – born on common grounds and values, with the aim of using sailing as a corporate communication vehicle towards the market and the nautical world. “Ingenuity, courage, innovation, responsibility are elements which unite us - explained Bona - for this reason we are facing together this challenge, which is clearly sporting but which also metaphorically represents the Company's history, philosophy and vision always turned towards the future, and is part of a path bringing IBSA ever closer to environmental and social sustainability, inclusion and integration. In this type of challenge, the solitary navigator stands out but, as in the industry, the commander exists as a function of his team. With IBSA, we first of all built a team”.

As for the team, we start with Sidney Gavignet as a coach: the very experienced French navigator laid the foundations and objectives, with a strict rule: always be prepared, to foresee all aspects of the challenge, on land and at sea. “Sidney put us in a position to divide this great challenge into many small steps. A long roadmap of stages to be reached, training and testing in preparation for the start, since building a challenge like the Route du Rhum from scratch in seven months is extremely demanding”. For the physical preparation part, Bona relied on Andrea Madaffari: he has been working with him for months on endurance and strength, as well as on the management of the energy peaks necessary during a regatta. “When sailing, one needs stamina and does a lot of pulling and hauling: you pull sheets and halyards, you need endurance and peak strength”, explained Bona. “We are working on this, as well as on the aerobic part”.

The choice of Sam Manuard as a designer was virtually natural,” recalled Bona, and is based on a solid relationship dating back to the time of the Mini class, on the sharing of a design vision and on the innovations that Bona was looking for his IBSA Class40. On the sails front, Bona chose Remi Aubrum, whom he entrusted with the choice of innovative materials, compatible with the rigorous box rule of the Class40. The last operational entry is that of the Boat Captain, the Breton expert Pierre-Edouard Regaud.

In recent months we have all been working with the same philosophy, that of the goals to be achieved day by day. We are working on fatigue management, on finding the best solutions in all aspects of the project. It was a huge team effort, between us and IBSA, that led us to yesterday’s technical launch, said Bona.

In the afternoon, at 5 pm, the IBSA Class40 made on board a truck the short journey between the shipyard and the marina that will host it, which is located in front of “Casa IBSA”, the operational headquarters. Alberto Bona now has one month to set up the boat and to qualify, by sailing a thousand miles by the end of August. On September 9, the actual launch – the ceremony that will officially make the Class40 enter the IBSA world – will take place in La Trinité-sur-Mer. In mid-September, Bona will participate in the Malouine Lamotte regatta; then, he will transfer his operational base to Saint-Malo, from where the first regatta of the three-year program will start.

We willtalk to sailing enthusiasts and to the entire IBSA world,” explained Bona, who also underlines the existence of a comprehensive sustainability project, incommon with IBSA: “Navigators are experts in circular economy; they live for long periods on the ocean, they replace fossil fuels with solar and wind energy, they recycle everything they can, they live in true harmony with the sea, that they help protect: this is a very important message that, together with IBSA, we wish to promote and share, using the solo oceanic challenge as a great metaphor of what can and must be done for the environment”.

In its program associated with sailing, IBSA is also committed to inclusiveness: in fact, the inclusive sailing projectinvolving the Associazione Velabili based at the Circolo Velico Lago di Lugano (Switzerland), the Société des Régates d’Antibes (France)and the Yacht Club Punta Ala (Italy)has also been activated. The project aims to support inclusive sailing by promoting initiatives involving people with disabilities in experiences in contact with the sea and the sailing world, and consists in supporting a team of disabled sailors in participating in the Special Olympics World Games of 2023 and in the purchase of Hansa 303 boats for the Clubs of Punta Ala and Antibes.


IBSA (Institut Biochimique SA) is a Swiss multinational pharmaceutical Company, founded in 1945 in Lugano. Today, its products are present in over 90 Countries on 5 continents, through the Company’s 17 subsidiaries located in Europe, China, and the United States. The company has a consolidated turnover of 800 million CHF, and employs over 2,000 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents, plus others under development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardiometabolic, respiratory, consumer health. It is also one of the largest operators worldwide in the area of reproductive medicine, and one of the world’s leaders in hyaluronic acid-based products. IBSA has based its philosophy on four pillars: Person, Innovation, Quality and Responsibility.

To view this piece of content from, please give your consent at the top of this page.

Contact information

IBSA Press Office – Italy
Martina Baldazzi – – mob: +39 339 222 9911
Valeria Riccobono – – mob: +39 392 9625892
Ornella Reccia – – mob. +39 329 393 1922

IBSA Press Office – Switzerland
Francesca Rossini – – mob: +41 77 417 93 72

About Business Wire

Business Wire
Business Wire

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kapruvia ® approved in Switzerland with additional regulatory decisions expected in H2 202219.8.2022 07:00:00 CEST | Press release

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia® will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. Swissmedic approval for Kapruvia® follows approvals by the U.S. Food and Drug Administration, by the European Medicines Agency, by the UK Medicines and Healthcare products Regulatory Agency, as well as by Health Canada. This press release features multimedia. View the full release here: “The approval of Kapruvia® in Switzerland is the next step on our journey to bring this breakthrough treatment to hemodialysis patients living with CKD-associated pruritus around the world,” said Dr. Klaus Henning Jensen, Chief Medical Officer of CSL Vifor. “There is a

European Commission Approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer19.8.2022 04:47:00 CEST | Press release

Celltrion Healthcare announced today that the European Commission (EC) has approved Vegzelma™ (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin®, for the treatment of metastatic breast cancer, non-small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer and cervical cancer. “The European Commission’s approval of Vegzelma™ will increase access to treatment for patients living with certain types of cancer at an affordable price,” said Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare. “With proven similarities in efficacy and safety compared to the reference product Avastin®, Vegzelma™ will be available to treat some of the most commonly diagnosed cancers, which collectively affect hundreds of thousands of European patients each year.” The EC approval of Vegzelma™ follows the recommendation for marketing authorisation issued by the Committee for Medi

Dermaliq Therapeutics announces first patient dosed in Phase 1b/2 trial evaluating DLQ02 for treatment of plaque psoriasis18.8.2022 18:27:00 CEST | Press release

Dermaliq Therapeutics, Inc. (Dermaliq), a private, clinical stage pharmaceutical company with a focus on dermatology, today announced first patient dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in patients with plaque psoriasis. “DLQ02 evaluates for the first time hyliQTM, a novel platform technology in dermatology to create best in-class topical therapies with superior bioavailability,” said Betsy Hughes-Formella, PhD, Chief Scientific Officer at Dermaliq. “Calcineurin inhibitors for the treatment of psoriasis are a standard of care when given orally, albeit being associated with significant risk for systemic side effects. DLQ02 is designed to overcome the challenges of topical delivery of this drug class with reduced risk profiles. We are convinced DLQ02 has the potential to transform topical psoriasis therapy for millions of patients.” The r

Aero Secures $65M in Series B Financing to Accelerate the Future of Premium Air Travel18.8.2022 18:00:00 CEST | Press release

Aero Technologies, Inc. the next-generation premium air travel company, which serves routes in both the US and Europe, today announced a $65M capital raise, $50M in Series B funding and $15M in convertible notes, for a total post-money valuation of $300M. The funding round was co-led by AlbaCore Capital Group, one of Europe’s leading alternative investment firms, and returning investors Expa and Keyframe Capital, with new investment from Capital One Ventures. This press release features multimedia. View the full release here: (Photo: Business Wire) Inspired by the golden age of aviation and designed for modern life, Aero is redefining semi-private air travel. Aero serves premium leisure travelers through private terminals, enriching the experience with personalized Concierge services - from booking to touchdown. With its fleet of sleek, black planes, Aero offers elevated, effortless guest experiences to curated destinations with

Veristat is Recognized on the 2022 Inc. 5000 List of America’s Fastest-Growing Private Companies18.8.2022 15:49:00 CEST | Press release

Veristat, global experts in clinical development, registration and post-marketing solutions proudly announces its recognition once again by Inc. Magazine as one of the 5000 fastest-growing private companies in the United States. Since its first appearance on the list in 2015, Veristat has significantly expanded in size, geographic reach and service offering to swiftly guide novel therapies through their clinical development process to regulatory approval and commercialization. Veristat’s team of scientific experts works collaboratively with clients in the biotech and pharmaceutical industries to overcome the many challenges associated with bringing to market products that address current medical shortcomings and maintain their good standing. “Being recognized as one of America’s Fastest-Growing Private Companies is a testament to Veristat’s ability to deliver innovative solutions, bold thinking and versatile engagement models to our clients,” stated Patrick Flanagan, Chief Executive Of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom